J. J. J. VAN Giezen
Research Subjects
Research Interests
J. J. J. VAN Giezen has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Jan-Arne Björkman
Department of BioScience, AstraZeneca R&D, Mölndal, Sweden
2 shared publicationsB.‐M. Wissing
Departments of BioScience
1 shared publicationF. Giordanetto
Lead Generation, AstraZeneca R&D Mölndal, Mölndal, Sweden
1 shared publicationHelen Zachrisson
1 shared publicationIan Kirk
SPDB, AstraZeneca R&D, Charnwood, UK
1 shared publicationJames Sidaway
Global Safety Assessment, AstraZeneca R&D, Alderly Park, UK
1 shared publication
Latest Publications
- 22 June 2011
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 17 (2) , 164-172
Ticagrelor Inhibits Adenosine Uptake In Vitro and Enhances Adenosine-Mediated Hyperemia Responses in a Canine Model
Aims: A routine secondary pharmacology screen indicated that reversibly binding oral P2Y12receptor antagonist ticagrelor could inhibit adenosine uptake in human erythrocytes, suggesting that ticagrelor may potentiate adenosine-mediated responses in vivo. The aim of this study was to further characterize the adenosine uptake inhibition in vitro and study possible physiological consequences of adenosine uptake inhibition by ticagrelor in an anesthetized dog model of coronary blood flow compared to dipyridamole. Methods and Results: We measured [2-3H]adenosine uptake in purified human erythrocytes and several cell lines in the presence of ticagrelor or the known uptake inhibitor dipyridamole as a comparator. Using an open-chest dog model (beagles), we measured the left anterior descending (LAD) coronary artery blood flow during reactive hyperemia after 1 minute occlusion or intracoronary infusion of adenosine before and after administration of vehicle, ticagrelor, or dipyridamole (each n = 8). Ticagrelor concentration-dependently inhibited adenosine uptake in human erythrocytes and in cell lines of rat, canine, or human origin. In the dog model, ticagrelor and dipyridamole dose-dependently augmented reactive hyperemia after LAD occlusion, as assessed by percentage repayment of flow debt relative to control (both Ps < .05). Ticagrelor and dipyridamole also dose-dependently augmented intracoronary adenosine-induced increases in LAD blood flow relative to control (both Ps < .05). Conclusion: Ticagrelor inhibits adenosine uptake in vitro and subsequently augments cardiac blood flow in a canine model of reactive hypoxia- or adenosine-induced blood flow increases. These findings suggest that ticagrelor may have additional benefits in patients with acute coronary syndrome beyond inhibition of platelet aggregation.
- 22 June 2011
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 17 (2) , 164-172
Ticagrelor Inhibits Adenosine Uptake In Vitro and Enhances Adenosine-Mediated Hyperemia Responses in a Canine Model
Aims: A routine secondary pharmacology screen indicated that reversibly binding oral P2Y12receptor antagonist ticagrelor could inhibit adenosine uptake in human erythrocytes, suggesting that ticagrelor may potentiate adenosine-mediated responses in vivo. The aim of this study was to further characterize the adenosine uptake inhibition in vitro and study possible physiological consequences of adenosine uptake inhibition by ticagrelor in an anesthetized dog model of coronary blood flow compared to dipyridamole. Methods and Results: We measured [2-3H]adenosine uptake in purified human erythrocytes and several cell lines in the presence of ticagrelor or the known uptake inhibitor dipyridamole as a comparator. Using an open-chest dog model (beagles), we measured the left anterior descending (LAD) coronary artery blood flow during reactive hyperemia after 1 minute occlusion or intracoronary infusion of adenosine before and after administration of vehicle, ticagrelor, or dipyridamole (each n = 8). Ticagrelor concentration-dependently inhibited adenosine uptake in human erythrocytes and in cell lines of rat, canine, or human origin. In the dog model, ticagrelor and dipyridamole dose-dependently augmented reactive hyperemia after LAD occlusion, as assessed by percentage repayment of flow debt relative to control (both Ps < .05). Ticagrelor and dipyridamole also dose-dependently augmented intracoronary adenosine-induced increases in LAD blood flow relative to control (both Ps < .05). Conclusion: Ticagrelor inhibits adenosine uptake in vitro and subsequently augments cardiac blood flow in a canine model of reactive hypoxia- or adenosine-induced blood flow increases. These findings suggest that ticagrelor may have additional benefits in patients with acute coronary syndrome beyond inhibition of platelet aggregation.
- 1 November 2009
- Published by Elsevier in Thrombosis Research
- Vol. 124 (5) , 565-571
Comparison of ticagrelor and thienopyridine P2Y12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis
- 1 November 2009
- Published by Elsevier in Thrombosis Research
- Vol. 124 (5) , 565-571
Comparison of ticagrelor and thienopyridine P2Y12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis
- 1 September 2009
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 7 (9) , 1556-1565
Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregation
- 1 September 2009
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 7 (9) , 1556-1565
Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregation
- Open Access
- 1 May 2008
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 10 (suppl_D) , D23-D29
Optimizing platelet inhibition
The platelet P2Y12 receptor plays a critical role in sustaining ADP-mediated platelet aggregation. Drawbacks of the thienopyridine clopidogrel, a prodrug of an irreversible P2Y12 antagonist, include the need for two-step metabolism to its active form and partial hydrolysis to its inactive metabolite. Both contribute to high variability in the degree of platelet inhibition and the irreversibility of binding complicates both acute and planned invasive treatments when rapid offset of antiplatelet activity is desired. Novel P2Y12 antagonists include the thienopyridine prasugrel and the selective, direct, reversible antagonists cangrelor (iv) and AZD6140 (oral). Prasugrel, also an irreversible antagonist, requires only one-step metabolism to active form and achieves greater inhibition of platelet aggregation (IPA) than clopidogrel. Recently published data indicate that this translates into improved efficacy. Like clopidogrel, prasugrel relies on new platelet generation for offset of effect. The direct reversible antagonists bind directly to the receptor, and the degree of IPA closely follows plasma drug concentrations. In addition to permitting more rapid offset of effect and greater and more consistent IPA than clopidogrel, direct reversible antagonists may exert additional beneficial effects via blockade of P2Y12 in vascular smooth muscle cells. Reversible antagonists also appear to exhibit a wider therapeutic window, showing reduced bleeding time prolongation per given degree of antithrombotic effect in experimental models. Ongoing large-scale Phase 3 clinical trials are examining cangrelor in patients with acute coronary syndromes (ACS) also undergoing percutaneous coronary intervention (PCI) and AZD6140 in ACS patients being treated with medical therapy, PCI, or coronary artery bypass grafting.
- 1 May 2008
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 10 (suppl_D) , D23-D29
Open AccessOptimizing platelet inhibition
The platelet P2Y12 receptor plays a critical role in sustaining ADP-mediated platelet aggregation. Drawbacks of the thienopyridine clopidogrel, a prodrug of an irreversible P2Y12 antagonist, include the need for two-step metabolism to its active form and partial hydrolysis to its inactive metabolite. Both contribute to high variability in the degree of platelet inhibition and the irreversibility of binding complicates both acute and planned invasive treatments when rapid offset of antiplatelet activity is desired. Novel P2Y12 antagonists include the thienopyridine prasugrel and the selective, direct, reversible antagonists cangrelor (iv) and AZD6140 (oral). Prasugrel, also an irreversible antagonist, requires only one-step metabolism to active form and achieves greater inhibition of platelet aggregation (IPA) than clopidogrel. Recently published data indicate that this translates into improved efficacy. Like clopidogrel, prasugrel relies on new platelet generation for offset of effect. The direct reversible antagonists bind directly to the receptor, and the degree of IPA closely follows plasma drug concentrations. In addition to permitting more rapid offset of effect and greater and more consistent IPA than clopidogrel, direct reversible antagonists may exert additional beneficial effects via blockade of P2Y12 in vascular smooth muscle cells. Reversible antagonists also appear to exhibit a wider therapeutic window, showing reduced bleeding time prolongation per given degree of antithrombotic effect in experimental models. Ongoing large-scale Phase 3 clinical trials are examining cangrelor in patients with acute coronary syndromes (ACS) also undergoing percutaneous coronary intervention (PCI) and AZD6140 in ACS patients being treated with medical therapy, PCI, or coronary artery bypass grafting.
- 26 April 2005
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 31 (02) , 195-204
Preclinical and Clinical Studies with Selective Reversible Direct P2Y12Antagonists
An important role for adenosine diphosphate (ADP)-induced platelet activation and aggregation was proposed more than 40 years ago. The clinical use of clopidogrel, a prodrug of an irreversible P2Y12 antagonist, has further proved the relevance of inhibiting signaling via the platelet-specific P2Y12 ADP receptor in the prevention of cardiovascular events. Pharmacological studies at AstraZeneca R&D Charnwood have identified direct, selective, and competitive P2Y12 antagonists, including cangrelor (also known as AR-C69931MX), which is suitable for intravenous administration, and AZD6140, which is suitable for oral administration. In preclinical use, these compounds predictably and effectively inhibited platelet aggregation without significant increases in bleeding time. In clinical use, these compounds may have significant advantages over current antiplatelet agents. This article summarizes preclinical and clinical data on cangrelor and AZD6140 and discusses the potential of these compounds as novel antiplatelet therapies.
- 26 April 2005
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 31 (02) , 195-204
Preclinical and Clinical Studies with Selective Reversible Direct P2Y12Antagonists
An important role for adenosine diphosphate (ADP)-induced platelet activation and aggregation was proposed more than 40 years ago. The clinical use of clopidogrel, a prodrug of an irreversible P2Y12 antagonist, has further proved the relevance of inhibiting signaling via the platelet-specific P2Y12 ADP receptor in the prevention of cardiovascular events. Pharmacological studies at AstraZeneca R&D Charnwood have identified direct, selective, and competitive P2Y12 antagonists, including cangrelor (also known as AR-C69931MX), which is suitable for intravenous administration, and AZD6140, which is suitable for oral administration. In preclinical use, these compounds predictably and effectively inhibited platelet aggregation without significant increases in bleeding time. In clinical use, these compounds may have significant advantages over current antiplatelet agents. This article summarizes preclinical and clinical data on cangrelor and AZD6140 and discusses the potential of these compounds as novel antiplatelet therapies.